Compare Gogoro Inc (GGR) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs HCA Health Inc — how do they compare? Gogoro Inc trades at $2.89 (market cap $56.21M), while HCA Health Inc trades at $449.15 (market cap $96.35B). The key difference: HCA Health Inc is far larger — about 1714.1× Gogoro Inc's market cap, and HCA Health Inc pays a 0.7% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and HCA Health Inc for 76 Days on average.
| GGR | HCA | |
|---|---|---|
Market Cap | $56.21M | $96.35B |
Volume | 14,026 | 1,079,453 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $545.13 |
52-Week Low | $2.20 | $361.32 |
Typical Hold Time | 14 Days | 76 Days |
Enterprise Value | $342.65M | $146.88B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.99, down 6.27% today, with a bullish technical signal from moving averages but negative profitability metrics including a -16.68% net income margin. Recent developments include new board appointments and a $61.8 million equity investment announced in October 2026. The company shows revenue growth from $281 million in 2025 to $286 million projected for 2026, though net losses persist.
The outlook remains cautious with 100% hold ratings from analysts. Investment appeal lies in the low P/S of 0.18 and EV/EBITDA of 6.38, but risks include sustained negative cash flow and high debt-to-asset ratio of 60%. Positive technical momentum contrasts with fundamental challenges in achieving profitability.
HCA Healthcare trades at $449.47, up 2.35% with bullish technical indicators and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $7.59 exceeding expectations, while revenue growth continues from $75.6B in 2025 to projected $78.0B in 2026. Analyst consensus remains strongly positive with 63% buy ratings and $461.12 price target, though legal investigations present headwinds.
The outlook remains favorable with solid patient demand and operational efficiency driving growth, though investors should monitor ongoing legal investigations and debt levels. Valuation appears reasonable with P/E of 14.92 and EV/EBITDA of 9.26, while technical support at $440 provides near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
